Cercar
01/01/2022
Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
Kuster S., Jordan S., Elhai M., Held U., Steigmiller K., Bruni C., Cacciapaglia F., Vettori S., Siegert E., Rednic S., Codullo V., Airo P., Braun-Moscovici Y., Hunzelmann N., Joao Salvador M., Riccieri V., Gheorghiu A.-M., Alegre Sancho J.J., Romanowska-Prochnicka K., Castellví I., Kötter I., Truchetet M.-E., López-Longo F.J., Novikov P.I., Giollo A., Shirai Y., Belloli L., Zanatta E., Hachulla E., Smith V., Denton C., Ionescu R.M., Schmeiser T., Distler J.H.W., Gabrielli A., Hoffmann-Vold A.-M., Kuwana M., Allanore Y., Distler O.. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open. 2022; 8(2)DOI:10.1136/rmdopen-2022-002477. PMID:36328401. IF:6.200(Q1/2D).
01/01/2022
How do Spanish Rheumatologists handle remission? Survey of knowledge and approach before and after a training workshop
Balsa A., González-Álvaro I., Sanmartí R., Corominas H.. How do Spanish Rheumatologists handle remission? Survey of knowledge and approach before and after a training workshop. Reumatologia Clinica. 2022; 18(9)DOI:10.1016/j.reuma.2021.08.002. PMID:34489191. IF:(Q/D).
01/01/2022
SER-SEPAR recommendations for the the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment
Narváez J., Díaz del Campo Fontecha P., Brito García N., Bonilla G., Aburto M., Castellví I., Cano-Jiménez E., Mena-Vázquez N., Nieto M.A., Ortiz A.M., Valenzuela C., Abad Hernández M.Á., Castrejón I., Correyero Plaza M., Francisco Hernández F.M., Hernández Hernández M.V., Rodríquez Portal J.A.. SER-SEPAR recommendations for the the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment. Reumatologia Clinica. 2022; 18(9)DOI:10.1016/j.reuma.2022.03.005. PMID:36064885. IF:(Q/D).
01/01/2022
SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosis
Rodríguez Portal J.A., Brito García N., Díaz del Campo Fontecha P., Valenzuela C., Ortiz A.M., Nieto M.A., Mena-Vázquez N., Cano-Jiménez E., Castellví I., Aburto M., Bonilla G., Hernández Hernández M.V., Hernández F.M.F., Correyero Plaza M., Castrejón I., Abad Hernández M.Á., Narváez J.. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosis. Reumatologia Clinica. 2022; 18(8)DOI:10.1016/j.reuma.2022.02.009. PMID:36085196. IF:(Q/D).